Helicobacter Pylori. Helicobacter pylori [H. pylori] as the cause of diseases classified elsewhere
Conditions
Interventions
Intervention 1: Intervention group 1: Patients in sequential therapy group received pantoprazole 20 mg twice daily for 10 days, amoxicillin 1000 mg twice daily for the first 5-day period followed by t
Sponsors
Bandare-abbas University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Patients who had not previously been treated for H. pylori Being older than 18 years Gastrointestinal symptoms such as nausea, vomiting, indigestion and melena Being a candidate for endoscopy Not responding to experimental therapy
Exclusion criteria
Exclusion criteria: Pregnant patients Lactating patients Patients with severe heart Liver disease Lung disease Kidney disease Patients with malignancies Being allergic to amoxicillin Being allergic to clarithromycin Being allergic to tinidazole Patient's dissatisfaction with participating in the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Helicobacter Pylori infection eradication rate. Timepoint: 4 weeks after the completion of treatment. Method of measurement: Urea breath test (UBT). | — |
Secondary
| Measure | Time frame |
|---|---|
| Mild drug side effects. Timepoint: 4 weeks after the completion of treatment. Method of measurement: Questionnaire, Physician's examination of patient's clinical symptoms.;Severe drug side effects. Timepoint: 4 weeks after the completion of treatment. Method of measurement: Questionnaire, Physician's examination of patient's clinical symptoms.;Drug intolerance. Timepoint: 4 weeks after the completion of treatment. Method of measurement: Questionnaire, Physician's examination of patient's clinical symptoms. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactHamid Mousavi
Bandare-abbas University of Medical Sciences
Outcome results
None listed